Microplastic pollution has emerged as a major global environmental and public health crisis. Recent oncological investigations now show that environmental polyethylene terephthalate micro- and nanoplastics (PET-MNPs) directly accelerate clear cell renal cell carcinoma (ccRCC) progression through defined intracellular molecular cascades. These findings highlight how non-biodegradable synthetic polymers cross biological barriers, accumulate in renal tissue, and disrupt essential metabolic processes.

Biological Bioaccumulation of PET Micro- and Nanoplastics

Environmental plastics degrade progressively into microscopic and nanoscopic fragments that enter the human body via ingestion, inhalation, and dermal absorption. Polyethylene terephthalate represents one of the most widely manufactured synthetic polymers worldwide, primarily utilized in single-use beverage containers, food packaging, synthetic textiles, and industrial fabrics. Because the human kidneys continuously filter massive volumes of circulating blood, renal tubular epithelial cells and interstitial tissues remain exceptionally vulnerable to plastic particle accumulation.

Recent experimental evaluations utilizing clear cell renal cell carcinoma cell models, specifically 786-O and CAKI-1 lines, demonstrate that neoplastic cells rapidly internalize PET-MNPs. Furthermore, in vivo evaluations using subcutaneous and orthotopic xenograft mouse models reveal that persistent exposure to these microscopic plastic fragments significantly accelerates tumor growth kinetics. Additionally, internalized particles promote aggressive cellular phenotypes, enhancing cell migration, invasion, and colony formation capabilities. Consequently, environmental microplastics act not merely as inert foreign material, but rather as active metabolic and signaling disruptors within renal tumor microenvironments.

Mitochondrial Oxidative Stress and Structural Impairment

Intracellular accumulation of PET-MNPs triggers profound metabolic perturbations centered within the mitochondria. Specifically, exposure to these nanoplastic polymers drives marked elevations in both generalized intracellular and organelle-specific mitochondrial reactive oxygen species (ROS). This profound mitochondrial superoxide accumulation correlates directly with severe organelle dysfunction.

Detailed biochemical analyses demonstrate that treated renal carcinoma cells undergo significant mitochondrial membrane depolarization, alongside substantial reductions in cellular adenosine triphosphate (ATP) production. Moreover, transmission electron microscopy reveals extensive mitochondrial ultrastructural abnormalities, including cristae disruption, organellar swelling, and outer membrane fragmentation. Concurrently, PET-MNP exposure leads to a marked decrease in superoxide dismutase 2 (SOD2) protein expression, alongside suppressed manganese superoxide dismutase (Mn-SOD) enzymatic activity. Therefore, the impairment of endogenous antioxidant defenses magnifies localized oxidative stress. This persistent oxidative microenvironment subsequently creates a permissive biological state that fuels downstream oncogenic signal transduction and metabolic reprogramming in renal neoplastic cells.

Activation of AKT/GSK3β/β-Catenin in ccRCC Progression

The escalation of mitochondrial ROS directly triggers an intracellular kinase cascade that governs clear cell renal cell carcinoma development. Mechanistic investigations indicate that PET-MNP exposure increases the phosphorylation of protein kinase B (AKT) at critical activating residues. Subsequently, activated AKT phosphorylates glycogen synthase kinase 3 beta (GSK3β) at Serine 9, an inhibitory site that suppresses GSK3β kinase activity.

Under basal physiological conditions, active GSK3β phosphorylates β-catenin to mark it for proteasomal degradation. However, PET-MNP-induced phosphorylation of GSK3β at Serine 9 disrupts this destruction complex. As a result, degradation-associated phosphorylation and ubiquitination of β-catenin decline dramatically. Consequently, β-catenin exhibits heightened cytoplasmic stability and translocates into the nucleus. Detailed time-course analyses further demonstrate that AKT activation precedes alterations in GSK3β and β-catenin, confirming that upstream AKT phosphorylation initiates this oncogenic axis. Through this precise signaling cascade, environmental plastic exposure sustains continuous Wnt/β-catenin pathway activation, thereby driving ccRCC progression.

Transcriptional Upregulation of Oncogenic Targets MYC and CCND1

Following nuclear accumulation, stabilized β-catenin forms active transcriptional complexes with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors. Chromatin immunoprecipitation quantitative polymerase chain reaction (ChIP-qPCR) assays reveal significantly increased β-catenin recruitment to the promoter and regulatory regions of pivotal oncogenes, notably MYC and CCND1 (Cyclin D1).

Reverse transcription-quantitative PCR (RT-qPCR) further confirms that this elevated promoter binding translates into robust transcriptional upregulation of MYC and Cyclin D1 mRNA transcripts. Overexpression of Cyclin D1 accelerates cell cycle transit through the G1/S transition, which directly promotes uncontrolled tumor cell proliferation. Meanwhile, elevated MYC expression coordinates metabolic rewiring, increases ribosomal biogenesis, and suppresses apoptotic triggers. Together, these transcriptomic changes reinforce the malignant phenotype of renal cancer cells. Thus, PET-MNP exposure directly fuels neoplastic proliferation by mobilizing key nuclear oncogenic drivers through sustained β-catenin transcriptional transactivation.

Experimental Validation and Molecular Reversal Strategies

To validate the causal role of mitochondrial oxidative stress in activating this proliferative signaling pathway, researchers conducted several targeted rescue and inhibition experiments. Administration of MitoTEMPO, a mitochondria-targeted antioxidant that scavenges superoxide radicals, successfully attenuated AKT phosphorylation, restored GSK3β activity, and diminished β-catenin nuclear accumulation in PET-MNP-exposed cells.

In addition, pharmacological inhibition of AKT or β-catenin, as well as genetic AKT knockdown using specific short interfering RNAs, abolished the pro-tumorigenic effects induced by microplastics. Furthermore, molecular rescue experiments employing a non-degradable β-catenin mutant (β-catenin-S33Y) maintained oncogenic activation despite microplastic withdrawal. Conversely, expression of a constitutively active GSK3β mutant (GSK3β-S9A) prevented β-catenin accumulation and blunted tumor progression. Collectively, these rigorous molecular interventions confirm that the mitochondrial ROS-associated AKT/GSK3β/β-catenin cascade represents the primary functional driver mediating PET-MNP-promoted malignancy in preclinical clear cell renal cell carcinoma models.

Clinical Considerations and Preventive Implications

These laboratory and preclinical findings hold significant implications for nephrologists, urologic oncologists, and environmental health specialists. While epidemiological studies must further characterize human kidney tissue microplastic burdens, these findings provide clear mechanistic proof that environmental contaminants actively modulate renal tumorigenesis.

Clinicians must recognize that microplastic exposure represents an insidious environmental risk factor that interacts with genetic and metabolic predispositions. For patients diagnosed with clear cell renal cell carcinoma, lifestyle modifications aimed at reducing plastic consumption—such as avoiding heated plastic food containers, utilizing glass or stainless steel water vessels, and reducing processed packaged food intake—may minimize further systemic xenobiotic accumulation. Furthermore, therapeutic targeting of mitochondrial oxidative stress or the AKT/β-catenin axis may present viable adjuvant strategies to mitigate pollution-promoted renal cancer growth. Continued translational research will help establish diagnostic biomarkers of microplastic burden and guide public health policies to reduce environmental plastic contamination globally.

Frequently Asked Questions

How do PET micro- and nanoplastics enter the human body and reach the kidneys?

PET micro- and nanoplastics enter the human body primarily through the ingestion of contaminated food and water, inhalation of airborne synthetic fibers, and direct dermal contact. Once absorbed across the gastrointestinal or alveolar epithelium, these tiny particles enter systemic circulation. Because the kidneys filter approximately 180 liters of blood daily, renal tubular epithelial cells and interstitial tissues frequently internalize and accumulate these circulating nanoparticles over time.

What specific molecular pathway links PET microplastic exposure to ccRCC progression?

PET microplastics trigger mitochondrial superoxide accumulation and membrane depolarization, which subsequently activates the AKT kinase. Activated AKT then phosphorylates GSK3β at Serine 9 to inhibit its activity, preventing the ubiquitination and degradation of β-catenin. Consequently, stabilized β-catenin accumulates in the nucleus and binds regulatory promoters of MYC and CCND1, significantly driving malignant cellular proliferation, invasion, and accelerated ccRCC progression.

Can antioxidant therapy reverse the oncogenic effects caused by microplastic exposure?

Preclinical studies demonstrate that targeted antioxidant therapy using agents like MitoTEMPO can effectively reverse microplastic-induced tumor promotion. By selectively scavenging mitochondrial reactive oxygen species, MitoTEMPO suppresses downstream AKT activation, restores GSK3β-mediated β-catenin degradation, and inhibits MYC and Cyclin D1 expression. While these experimental results provide valuable proof-of-concept for mitochondrial targeting, comprehensive clinical trials remain necessary to evaluate antioxidant efficacy in human renal cancer patients.

Disclaimer: This content is for informational and educational purposes only and is intended for healthcare professionals. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Wu XH et al. Environmental Polyethylene Terephthalate Micro- and Nanoplastics Promote Clear Cell Renal Cell Carcinoma Progression Through Mitochondrial ROS-Associated AKT/GSK3β/β-Catenin Signaling. Small. 2026 Aug 27. doi: 10.1002/smll.75494. PMID: 42656173.
2. Ye S, Xiang J, Zhou S, et al. Polystyrene Microplastics Exposure Aggravates Clear Cell Renal Cell Carcinoma Progression via the NF-κB and TGF-β Signaling Pathways. Adv Sci (Weinh). 2025;12(45):e2518500.
3. Campanale C, Savino I, Massarelli C, Uricchio VF. Detrimental effects of microplastic exposure on kidney function and renal cellular homeostasis. Front Toxicol. 2025;7:1489201.
4. Kishore B, Joshi A, Verma P. Cellular and molecular toxicity of environmental microplastics: Oxidative stress, mitochondrial dysfunction, and oncogenic signaling cascades. Environ Sci Pollut Res Int. 2024;31(12):18902-18918.